Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial.

Breast (Edinburgh, Scotland)·2026
Same author

New Perspectives in the Management of Triple-Negative Breast Cancer.

Breast care (Basel, Switzerland)·2025
Same author

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.

NPJ breast cancer·2025
Same author

Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance.

Cellular oncology (Dordrecht, Netherlands)·2025
Same author

Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.

Breast (Edinburgh, Scotland)·2025
Same author

Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.

Drugs·2025
Same journal

Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial.

Breast care (Basel, Switzerland)·2026
Same journal

Feasibility and Oncologic Outcomes of Breast-Conserving Surgery for Multifocal and Multicentric Breast Cancer: A Retrospective Comparative Cohort Study.

Breast care (Basel, Switzerland)·2026
Same journal

Breast Conservation Therapy vs. Mastectomy Survival in Young Breast Cancer Patients: Systematic Review and Meta-Analysis.

Breast care (Basel, Switzerland)·2026
Same journal

Gender Disparities in Response to Neoadjuvant Therapy for Early-Stage Breast Cancer: A Propensity Score-Matched Analysis of the SEER Database.

Breast care (Basel, Switzerland)·2026
Same journal

The Importance of Continued Vigilance after Risk-Reducing Mastectomy in BRCA Carriers: A Case Report.

Breast care (Basel, Switzerland)·2026
Same journal

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Nov 21, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.2K

Biomarkers in Her2- Positive Disease.

Eva Valentina Klocker1, Christoph Suppan1

  • 1Department of Oncology, Medical University of Graz, Graz, Austria.

Breast Care (Basel, Switzerland)
|January 15, 2021
PubMed
Summary
This summary is machine-generated.

Biomarkers for Her2-positive breast cancer are crucial. While hormone receptor and Her2 status guide treatment, further research is needed for other markers like PD-L1 and TILs to improve patient outcomes.

Keywords:
BiomarkerBreast cancerHer2

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

466
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K

Related Experiment Videos

Last Updated: Nov 21, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.2K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

466
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K

Area of Science:

  • Oncology
  • Biomarker Research
  • Breast Cancer Therapeutics

Background:

  • Breast cancer is a complex disease with established prognostic and predictive markers like hormone receptor (HR) and human epidermal growth factor receptor 2 (Her2) status.
  • While Her2 is a key therapeutic target, treatment resistance, cardiotoxicity, and suboptimal responses necessitate the exploration of additional biomarkers.

Purpose of the Study:

  • To investigate the clinical impact of various biomarkers in Her2-positive breast cancer.
  • To evaluate the role of Her2 mutations, heterogeneity, HR, PIK3CA, PTEN, PD-L1, TILs, miRNA, and BRCA mutations in treatment decisions and outcomes.

Main Methods:

  • Comprehensive analysis of biomarkers including genetic mutations (Her2, PIK3CA, BRCA), protein expression (HR, PD-L1), immune cell infiltration (TILs), and non-coding RNAs (miRNA).
  • Correlation of biomarker status with clinical impact in patients with Her2-positive breast cancer.

Main Results:

  • HR status and Her2 status, including PIK3CA mutations, are currently influential in treatment decisions for Her2-positive breast cancer.
  • Biomarkers such as PD-L1 status and TILs show promise as future predictive markers.
  • The clinical significance of BRCA mutations, Her2 mutations, and miRNA requires further elucidation.

Conclusions:

  • Current biomarkers are insufficient for optimal clinical practice in Her2-positive breast cancer.
  • Additional research is essential to identify and validate novel biomarkers for improved patient management.
  • Antibody-drug conjugates (ADCs) like T-DM represent established treatment strategies, particularly in Her2-positive disease.